Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.70 |
| ▸ | CA1 | P00915 | 3/20 | 0.70 |
| ▸ | CA2 | P00918 | 3/20 | 0.70 |
| ▸ | CA9 | Q16790 | 3/20 | 0.70 |
| ▸ | CLTC | Q00610 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | POLB | P06746 | 4/20 | 0.64 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3856490 | 0.89 | CA12 (0.76) | CA12CA1CA2CA9CLTC | |
| SCHEMBL14636119 | 0.85 | CA12 (0.78) | CA12CA1CA2CA9CLTC | |
| SCHEMBL2280848 | 0.83 | CA12 (0.71) | CA12CA1CA2CA9CLTC | |
| SCHEMBL4235535 | 0.83 | CLTC (0.73) | CA12CA1CA2CA9CLTC | |
| SCHEMBL2280844 | 0.83 | CA12 (0.71) | CA12CA1CA2CA9CLTC | |
| SCHEMBL4234600 | 0.82 | CLTC (0.59) | CA12CA1CA2CA9CLTC | |
| SCHEMBL5116172 | 0.82 | MEN1 (0.66) | CA12CA1CA2CA9CLTC | |
| SCHEMBL5120849 | 0.80 | FTO (0.68) | CA12CA1CA2CA9CLTC | |
| SCHEMBL5158664 | 0.79 | CLTC (0.76) | CA12CA1CA2CA9CLTC | |
| SCHEMBL5162692 | 0.79 | CLTC (0.76) | CA12CA1CA2CA9CLTC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | claimed |
| EP-1931637-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2008-06-18 | — | — | EP | claimed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | claimed |
| WO-2007030940-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | claimed |
| US-7148352-B2 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-12-12 | — | — | US | claimed |
| US-6468990-B1 | ADMINISTERING COMPOUNDS HAVING ELECTRONEGATIVE GROUPS WHICH INTERACT WITH CERTAIN LYSINE RESIDUES IN NERVE GROWTH FACTOR AND/OR HYDROPHOBIC MOIETY WHICH INTERACTS WITH HYDROPHOBIC REGION FORMED BY CERTAIN ISOLEUCINE AND PHENYLALANINE RESIDUES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-10-22 | — | — | US | claimed |
| US-20090215814-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-08-27 | — | — | US | disclosed |
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | disclosed |
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | disclosed |
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070078137-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030940-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | disclosed |
| US-7148352-B2 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-12-12 | — | — | US | disclosed |
| US-20030186901-A1 | Method of inhibiting neurotrophin-receptor binding | MINE SAFETY APPLIANCES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-6468990-B1 | ADMINISTERING COMPOUNDS HAVING ELECTRONEGATIVE GROUPS WHICH INTERACT WITH CERTAIN LYSINE RESIDUES IN NERVE GROWTH FACTOR AND/OR HYDROPHOBIC MOIETY WHICH INTERACTS WITH HYDROPHOBIC REGION FORMED BY CERTAIN ISOLEUCINE AND PHENYLALANINE RESIDUES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-10-22 | — | — | US | disclosed |
| EP-1226121-A1 | METHOD OF INHIBITING NEUROTROPHIN-RECEPTOR BINDING | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-07-31 | — | — | EP | disclosed |
| WO-2000069829-A1 | METHOD OF INHIBITING NEUROTROPHIN-RECEPTOR BINDING | QUEEN'S UNIVERSITY (CA) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215814-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | CA12 2567/4885CA1 1178/4885CA2 1798/4885 |
| US-20070078137-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | CA12 2567/4885CA1 1178/4885CA2 1798/4885 |
| US-20030186901-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | CA12 2650/4885CA1 1142/4885CA2 1630/4885 |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | CA12 1700/4885CA1 847/4885CA2 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.